This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical…Read More
You might also be interested in reading Party In The USA: Ripple Gets Ready To Properly Celebrate Triumph Over SEC.